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Background
Actinidin (Act d 1) is a cysteine protease and major aller-
gen of kiwifruit with diagnostic significance. It is the
most abundant of the 11 kiwifruit allergens recognized
and has been identified as a marker molecule of kiwifruit
allergy. However, the mechanism underlining the oral
route of exposure and sensitization to this allergen has
yet to be elucidated. Working under the hypothesis that
food proteases, as was shown for some inhalatory aller-
genic proteases, could reach the intestinal mucosa and
surpass this barrier through proteolytic activity, we exam-
ined the following: Does Act d 1 have the ability to resist
gastrointestinal digestion and reach the intestinal mucosa
in a biologically active form? Upon reaching the intestinal
mucosa does Act d 1 enhance permeability of the intest-
inal barrier by disrupting tight junctions?
Method
In vitro analysis of Act d 1 digestion stability in simulated
conditions of the gastrointestinal tract was performed by
means of SDS-PAGE, zymography, ESI-TOF and immu-
noelectrophoresis. In addition, the influence of Act d 1 on
tight junctions of Caco-2 cells was assessed by immuno-
fluorescence and by measuring changes in transepithelial
resistance and FITC-dextran leakage across cell mono-
layers. In vivo studies were performed to determine the
effect of Act d 1 on intestinal permeability in mice.
Results
Act d 1 isolated from kiwifruit under native conditions
retained its primary structure, immunological reactivity
and proteolytic activity after 2 h of simulated gastric diges-
tion, followed by 2 h of simulated intestinal digestion.
Exposure of confluent Caco-2 cells to Act d 1 reduced the
transepithelial resistance of cell monolayers by 18.1% after
1h (P < 0.01) and 25.6% after 4 h (P < 0.001). The loss of
barrier function was associated with leakage of FITC-dex-
tran across the monolayers. Confocal microscopy revealed
that Act d 1 treatment lead to disruption of tight junction
proteins occludin and ZO-1. None of these effects were
observed with heat inactivated Act d 1. In vivo measure-
ments of intestinal permeability in mice showed that
following administration of 40 kDa FITC-dextran by
oral gavage, significantly higher concentrations of FITC-
dextran (2.33 µg/mL) were later detected in the sera of
Act d 1 treated mice in comparison to the control group
(0.5 µg/mL, P < 0.05).
Conclusion
Our findings show that Act d 1 is capable of reaching the
intestinal mucosa in a proteolytically active and immunor-
eactive state and that it causes protease-dependent disrup-
tion of tight junctions in Caco-2 cells and induces
intestinal permeability in mice. To the best of our knowl-
edge, Act d 1 is the first food allergen whose proteolytic
activity has been linked to breach of the epithelial barrier
as a possible mechanism of sensitization.
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